PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Aflibercept - Central retinal vein occlusion

PAD Profile : Aflibercept - Central retinal vein occlusion

Keywords :
CRVO, RVO
Brand Names Include :
Eylea

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 October 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends aflibercept (Eylea®) as a treatment option for the first line treatment of visual impairment caused by macular oedema secondary to central retinal vein occlusion in line with NICE TA 305 (February 2014) and the NICE FAQ document relating to local formularies (link to document below). Aflibercept will be considered RED on the traffic light system

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More